Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announces results from the FRUSICA-2 registration clinical trial of the fruquintinib and sintilimab combination for the treatment of patients with ...
AdvanCell to present promising clinical trial results of ADVC001, a novel Lead-212-based PSMA-targeted alpha therapy for prostate cancer, at ESMO 2025 Results from the Phase 1b dose escalation of the ...
The inclusion of the iStatis Syphilis Antibody Test in the ARTG supports Australia’s national strategy to expand testing and reduce sexually transmitted infections. By providing fast, reliable ...
Carlsbad, CA, Oct. 12, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the official launch of C10 Cryptocurrency Asset Treasury (DAT) purchases: Why ...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients ...
EarlyHealth Group, a global pharmaceutical services and life sciences solutions company, has acquired a 50 % equity stake in CYB3R Limited, one of the Gulf’s fastest-growing cybersecurity firms ...
The U.S. regulatory application for DB-OTO is planned for later this year, pending discussions with the U.S. Food and Drug Administration (FDA). DB-OTO received Orphan Drug, Rare Pediatric Disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback